Business ❯ Pharmaceutical Industry

Market Dynamics

Pricing Strategies Drug Pricing Drug Pricing Strategies Drug Sales Generic Drugs Competition Drug Competition Generic Competition Product Launch Pricing Issues Patent Expiration Cost Management Export Trends Drug Development Investment Strategies Stock Performance Investment Trends Supply Chain Patents Stock Market Impact Generics Competitors Investor Reactions Tariffs Investment Product Protection Strategies Revenue Generation Innovation Drug Approval Process Innovation Strategies Drug Demand Price Control Competition in Pharmaceuticals Drug Costs Weight Loss Drug Market Pharmacy Benefit Managers Price Concessions Telehealth Services Import Regulations Partnerships Vaccine Development Monopolies Profitability Risks Price Negotiation Export Strategies Biosimilar Development Export Challenges Production Costs U.S. Market Debt Issues Supplier Relations Competition Levels Pricing Models Sales Volumes Competition Laws Product Safety Competitiveness Cancer Therapies Supply Chain Issues Sales Performance Digital Therapeutics Eli Lilly Generic Drug Pricing Drug Approval Sales Forecasting Stock Market Apothecary Economics Pricing Pressure Price Increases Competitive Analysis Consumer Access Weight Loss Drugs Product Development China Anti-Obesity Medications Regional Market Share Generic Medications Consumer Behavior

CVS Caremark Restores Zepbound and Adds Lilly’s Foundayo to Standard Formularies

CVS says the change will expand treatment options to lower costs for tens of millions of commercially insured people.

India Tightens Oversight of GLP-1 Drugs as Semaglutide Generics Proliferate

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Analyses Find Limited Savings as TrumpRx Reaches 54 Drugs

Novo Nordisk Licenses Vivtex Platform in $2.1 Billion Push for Oral Obesity and Diabetes Drugs

FDA Expands Addyi Use to Postmenopausal Women, Including Those Over 65

WHO Endorses Long-Term GLP-1 Use for Obesity as Indian Ruling Opens Production and Safety Alerts Expand

Sarepta Shares Plunge After ESSENCE Phase 3 Miss in Duchenne Trial

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

FDA Approves Weekly Leqembi Autoinjector for At-Home Maintenance in Early Alzheimer’s

FDA Flags Possible License Revocation for Sarepta’s Elevidys